Intellia Therapeutics (NTLA) Shares Outstanding (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Shares Outstanding (Entity) of $120.4 million for Q1 2026, up 16.33% year-over-year from $103.5 million in Q1 2025, and up 3.55% quarter-over-quarter from $116.3 million in Q4 2025.
Intellia Therapeutics (NTLA) Shares Outstanding (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Shares Outstanding (Entity) for 12 consecutive years, with $120.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 16.33% year-over-year to $120.4 million; the TTM figure through Mar 2026 stood at $120.4 million (up 16.33% YoY), while the FY2025 annual figure was $116.3 million, up 14.0% from the prior year.
- Shares Outstanding (Entity) grew to $120.4 million in Q1 2026 per NTLA's latest filing, from $116.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $120.4 million in Q1 2026 and bottomed at $75.6 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $96.1 million across 5 years, with a median of $96.3 million in 2024.
- On a YoY basis, Shares Outstanding (Entity) climbed as much as 122763.72% in 2022 and fell as far as 3.02% in 2022.
- Intellia Therapeutics' Shares Outstanding (Entity) stood at $87.1 million in 2022, then climbed by 6.77% to $93.0 million in 2023, then climbed by 9.71% to $102.0 million in 2024, then increased by 14.0% to $116.3 million in 2025, then grew by 3.55% to $120.4 million in 2026.
- Business Quant data shows NTLA's Shares Outstanding (Entity) at $120.4 million in Q1 2026, $116.3 million in Q4 2025, and $115.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 133.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.48 Mn |
| Mar 31, 2026 | 118.49 Mn |
| Dec 31, 2025 | 108.38 Mn |
| Sep 30, 2025 | 110.19 Mn |
| Jun 30, 2025 | 103.73 Mn |
| Mar 31, 2025 | 103.50 Mn |
| Dec 31, 2024 | 98.85 Mn |
| Sep 30, 2024 | 101.00 Mn |
| Jun 30, 2024 | 96.98 Mn |
| Mar 31, 2024 | 95.50 Mn |
| Dec 31, 2023 | 88.77 Mn |
| Sep 30, 2023 | 88.65 Mn |
| Jun 30, 2023 | 88.19 Mn |
| Mar 31, 2023 | 87.77 Mn |
| Dec 31, 2022 | 76.97 Mn |
| Sep 30, 2022 | 76.05 Mn |
| Jun 30, 2022 | 75.82 Mn |
| Mar 31, 2022 | 74.75 Mn |
| Dec 31, 2021 | 70,894.00 |
| Sep 30, 2021 | 73.71 Mn |